Crystal habit modification and polymorphic stability assessment of a long-acting β2-adrenergic agonist

Citation:
Tulcidas, A, Lourenço NMT, Antunes R, Santos B, Pawlowski S, Rocha F.  2019.  Crystal habit modification and polymorphic stability assessment of a long-acting β2-adrenergic agonist. CrystEngComm. 21:3460-3470.: The Royal Society of Chemistry

Abstract:

Properties such as particle orientation{,} flowability{,} packing{,} compaction{,} syringeability{,} suspension stability and dissolution are the most influenced by changes in the crystal habit and polymorphic form of a drug substance. The crystal habit of a drug substance (long-acting β2-adrenergic agonist (LABA)){,} as well as its purity and polymorphic stability{,} was studied after performing slurry tests with 1{,}2-dimethoxyethane : heptane solution at 50 °C. In these slurry tests{,} the product was kept suspended and undissolved{,} with agitation{,} for polymorphic conversion evaluation. Since no significant modifications were observed in the crystal shape and dimensions at 50 °C{,} a new slurry test was performed at a temperature above the melting point of the starting material (80 °C). In the latter test{,} it was possible to obtain crystals with increased dimensions by 480% compared with the starting material. Additionally{,} the desired polymorphic form (form I) was obtained as well as an acceptable purity of approximately 99%. These are promising results{,} not only for downstream purposes{,} but also concerning the bioavailability of the drug substance. This work shows that working at a temperature higher than the melting point of the compound seems to modify the crystal habit of the product.

Notes:

n/a

Related External Link